You are here: Industry Insights > T cell

News List

NIHR study shows high efficacy of booster vaccines PharmaTimes
December 06, 2021
The news arrives after the tenth recorded positive Omicron case in Scotland, which the government has confirmed has no previous connection to the previous nine.
IGM Biosciences Appoints Chris Takimoto as CMO firstwordpharma
July 30, 2021
IGM today announced the appointment of Chris H. Takimoto, M.D., Ph.D., F.A.C.P., to the role of Chief Medical Officer, effective today. Dr. Takimoto will be responsible for global development of IGM's clinical pipeline of proprietary IgM antibodies.
Sana Biotechnology Enters Long-Term Lease to Establish Manufacturing Facility to Enable Its Gene and Cell Therapy Product Candidates firstwordpharma
July 15, 2021
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it has entered into a lease agreement to develop a 163,000 square foot manufacturing facility in Fremont, California.
Fox Chase Researcher Receives NIH Grant to Advance Treatment of Immune Diseases Using Genome Editing firstwordpharma
June 29, 2021
A Fox Chase Cancer Center researcher has received a grant of approximately half a million dollars from the National Institutes of Health (NIH) to identify disease-causing T cell defects.
Study shows SARS-CoV-2 variants unlikely to affect T cell responses firstwordpharma
May 27, 2021
In a new study, scientists at The Hong Kong, S.A.R., China University of Science and Technology (HKUST) have revealed that most T cell epitopes known to be targeted upon natural infection are seemingly unaffected by current SARS-CoV-2 variants.
Artificial intelligence model predicts which key of the immune system opens the locks of coronavirus worldpharmanews
April 26, 2021
The human immune defense is based on the ability of white blood cells to accurately identify disease-causing pathogens and to initiate a defense reaction against them.
Oxford Immunotec Submits Emergency Use Authorization Request to the FDA and CE Marks T-SPOT®.COVID, a Test for the Detection of a Cell Mediated (T cell) Immune Response to SARS-CoV-2 Infection prnasia
March 05, 2021
Oxford Immunotec Global PLC., a global, high-growth diagnostics company, announced that today it has released the T-SPOT.COVID test, a CE marked ELISPOT based test intended for qualitative detection of a cell mediated (T cell) immune response to ...
UK to collaborate with Oxford Immunotec to evaluate COVID-19 vaccine T cell responses expresspharma
October 23, 2020
T cell immunity is thought to be essential to protect against infection from the SARS-COV-2 coronavirus and could provide longer-term immunity than antibodies.
UK’s SARS-CoV-2 vaccine candidate is safe and induces antibody and T cell response europeanpharmaceuticalreview
July 22, 2020
Data released from the Phase I/II trial of the ChAdOx1 COVID-19 vaccine candidate suggests it elicits an immune response with no adverse effects.
Berkeley Lights Launches T Cell Receptor Sequencing Kit to Increase Efficiency of T Cell Receptor Discovery prnasia
March 06, 2020
The TCRseq Kit enables Berkeley Lights platform users to first characterize the T cell function using the Berkeley Lights Cell Therapy Development Suite and then only sequence the T cells that matter.

Previous page 1 2 Next page